Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 01, 2015 4:27 PM ET

Pharmaceuticals

Company Overview of C & O Pharmaceutical Technology Holdings Limited

Company Overview

C & O Pharmaceutical Technology (Holdings) Limited engages in the research and development, manufacture, marketing, and distribution of branded and third party pharmaceutical products primarily in China. The company offers anti-infection and gastrointestinal drugs, drugs for ageing adults, and specialized drugs. Its products are used for various indications, such as skin soft tissues infections, analgesic and antipyretic, indigestion or gastro esophageal reflux disorder, respiratory tract infections, otitis media, sinusitis, acute pharyngitis, UTI, hypertension, migraine, pancreatitis, upper gastrointestinal hemorrhage, pancreatic fistula, intestinal fistula, biliary fistula, breast cancer, ...

911-12 Silvercord Tower 2

30 Canton Road

Tsim Sha Tsui,  

Hong Kong

Founded in 2003

Phone:

852 2806 0109

Fax:

852 2887 8445

Key Executives for C & O Pharmaceutical Technology Holdings Limited

Chief Financial Officer
Age: 45
Executive Director
Age: 46
Executive Director
Executive Director
Executive Director
Compensation as of Fiscal Year 2015.

C & O Pharmaceutical Technology Holdings Limited Key Developments

C & O Pharmaceutical Technology (Holdings) Limited Launches First Rabeprazole Sodium for Injection

Shionogi & Co. Ltd. announced that its subsidiary C & O Pharmaceutical Technology (Holdings) Limited launched the first Rabeprazole Sodium for Injection (®) in China, on September 29 2014, which was developed by C&O itself. Proton-pump inhibitors (PPIs) inhibit gastric acid secretion by blocking the final stage of gastric acid secretion. ®, developed by C&O, belongs to the second generation of proton pump inhibitors and it is the only injectable rabeprazole product for the treatment of peptic ulcer in China. ® shows a rapid and long lasting gastric antisecretory activity and not easily metabolized by human drug metabolizing enzymes such as cytochrome P450s. Its clinical studies demonstrated that there is less concern for individual differences in efficacy and drug-drug interactions. The launch of ® that has the rapid and long lasting acid suppression activity is expected to contribute to the treatment of peptic ulcer in China by satisfying the unmet medical need of patients and healthcare providers as a new treatment option for gastric or duodenal ulcer which cannot accept oral treatment due to bleeding.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact C & O Pharmaceutical Technology Holdings Limited, please visit www.changao.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.